The extracorporal hemocorrection methods of treatment of bronchial asthma is successful in 100% of the cases:
The complex therapy conducted with such illnesses as: Allergic rhinitis, Atopic dematitis, Quincke's edema, Urticaria, Pollinosis - within a short time eliminate the manifestations of the disease and obtain a prolonged and steadfast remission
- in suppressing the active disease
- maintains remission for 10 - 12 months and more
- in hormone dependent cases of bronchial asthma supporting hormonal therapy is either completely suspended or the period of doses of the hormonal preparations are reduced to a minimum
This result is reached due to:
- The application of Extracorporal Immunopharmacotherapy methods, which changes the activity of the immune system to a desirable direction without reducing the potential immuno protection of the organism as a whole
- the Extracorporal detoxication methods, which are capable of removing ballast and toxic substances from an organism
- the methods of Extracorporal pharmacotherapy, which provide the delivery of medical products directly into the center of the pathological process
The efficiency of extracorporal hemocorrection technologies can be considered in the example of - Bronchial asthma.
Referring to the American Thoracic Society (1987) bronchial asthma is understood to be "a clinical syndrome, which is characterized by an increased sensitivity of the tracheobronchial tree to different stimuli. The basic physiological display of this hypersensitivity is the labile obstruction of the respiratory ways". It is suspected that 2% of the global population suffer from bronchial asthma. As a result, nearly 2 million people die of this disease annually. There has been a marked increase of the disease of bronchial asthma in all countries in recent years. This has been caused primarily by ecological conditions.
Currently it is agreed that there are two basic classifications of bronchial asthma - exogenous and endogenous. In the first variant of bronchial asthma there is an obvious external provoker of asthma attacks. In the second variant - the external provoking factor is impossible to define.
Several factors play a roll in the etiology of bronchial asthma. On one hand, genetic factors create a background for the development of the disease. The genetically predetermined instability of cellular membranes, the infringement of information interrelation of cell- regulators of the immune system are thought to be such factors. On the other hand there are external factors such as household, food, bacterial, and medicinal allergens.
In the pathogenesis of bronchial asthma a role is played by both immune as well as non immune mechanisms. From the immune reactions, the first type of allergic reactions on Coomb's classification has the greatest value. This type of reaction is named Reagin, or the IgE-mediated allergic reaction. In essence it states that in repeated contacts with any allergen an organism develops a large amount of specific immunoglobulins - IgE. These immunoglobulins possess the ability to quickly contact the membranes of corpulent cells on which there are special receptors specific to Fc-fragments IgE (Fig. 1).
Fig.1. The synthesis of immunoglobulines E (IgE) by the immune system (IS) is in response to repeated hits of an organism by an antigen (AG) and subsequent fixing of IgE by the Fc-fragments to specific receptors on the membranes of mastocytes.
When an organism of the patient is hit by a specific antigene there is a linkage of two IgE molecules, which are fixed on a membrane of a corpulent cell. As a result, there is an activation of a corpulent cell and an emission from that cell of biologically active substances which cause an immuno inflammatory process in a wall of a bronchial tube, a bronchospasm, stimulation or secretion of slime bronchial glands. The asthmatic attack then develops. Schematically these processes are presented in Fig. 2.
Fig. 2.The linkage of an antigen by immunoglobulines E, the activation of a corpulent cell and a biologically active substance (BAS) being released from it, causing an inflammatory process in a wall of a bronchial tube and the narrowing of its gleam.
Much less often a bronchial reaction develops with the third type of allergic reaction (immunocomplex) and with the fourth type (cellular). The scheme of development of the pathological process of types of allergic reactions is a little different. But biologically active substances released from mastocytes also are active in the final stages of these reactions.
Treatment of bronchial asthma is subdivided into the treatment of the developed asthmatic attack, the treatment of the aggravation of a bronchial asthma, and the treatment of an unstable remission of a bronchial asthma. We are primarily interested in the last two courses of treatment of bronchial asthma. Traditional medicamentous therapy of bronchial asthma at these stages includes such basic preparations as, methylxanthines (aminophylline), and β 2- adrenoceptor agonists (Berotec, Ventolin, etc.), cholinergic antagonists (Atropine), preparations which block the output of biologically active substances from mastocytes (Intal, Zaditen) and glucorticoid hormones. In order to lower the sensitivity of an organism to allergens, the process of giposensibilization is used. This provides cleansing of the chronic infection centers.
Methods of extracorporal hemocorrection are also recommended as treatments of bronchial asthma. In the application of these extracorporal hemocorrection methods to bronchial asthma such as plasmapheresis, hemosorbtion has been used for quite some time. However, the use of these methods have been associated with certain problems. As we already know from describing patogenesis diseases, IgE are localized primarily in fabrics, and a small amount circulates in a blood groove.
To effectively remove them from a blood groove the methods of plasmapheresis and specially, hemosorption are rather problematic. Upon aggressively applying these techniques there is a high probability of developing the so-called "syndrome of a ricochet". The essence of this syndrome consists of the following. In an organism, the regulation of synthesis of many substances is carried out by the principle of feedback. Therefore the organism quite often answers active removal of any metabolite activization of processes of synthesis of a metabolite.
Frequently this reaction is directed to the restoration of the initial concentration of metabolite, and it appears so active that the concentration of metabolite finally rises above the initial concentration. This is the example in our case - after applying the above stated methods extracorporal hemocorrection, maintenance of IgE in an organism, can later rise to higher levels than earlier. As a result, instead of improvement of the condition - it is possible to aggravate the illness.
As we have already mentioned, we generally do not apply the first generation methods of extracorporal hemocorrection (plasmapheresis, absorbtion). These methods only serve as a means for us to receive substrata for further updating using methods of extracorporal hemocorrection of the 2nd and 3rd generations.
For the treatment of bronchial asthma we have also developed the complex programs which include various extracorporal hemocorrection technologies, used in solving certain problems in the correction of the pathological process. These programs necessarily consider individual initial features of the illness in a specific patient. Usually our programs of treatment of bronchial asthma include the following basic components:
- the technologies of the incubation of cellular masses with glucocorticoids - which make it possible to decrease the pathologic hyperactivity of the immune system, therefore stabilizing the cellular membranes;
- the procedures of the cryomodification of autoplasma - which makes it possible to eliminate immunoglobulins and immune complexes from the blood flow;
- the methods of cytapheresis - which selectively remove from the blood flow the cells which enable the development of the pathologic process.
Recently, the procedure of thermoplasmasorbtion has been successfully applied in the treatment of bronchial asthma. The application of this technology of extracorporal hemocorrection in the treatment of bronchial asthma was determined by its ability to block Fc-fragments of IgE . As a result, the same molecules of IgE continue to circulate within the blood flow but they are proven incapable of becoming fixed to the surface of membranes of mastocytes which means that even being connected subsequently with the beginning allergen, they cannot activate the mastocytes and develop the output of biologically active substance, which in turn causes the development of the assault of bronchial asthma. This procedure also assures that the development of the "ricochet" syndrome will be avoided. Indeed, the initial content of IgE in the organism does not change, it simply loses its pathologic activity and the organism no longer needs to synthesize them (Fig. 3.).
Fig. 3. Performing the method of thermaplasmasorbtion (TPS) allows the inactivation of IgE, blocking their trailer Fc-fragments, but not reducing their concentration in an organism. The immune system in this case "does not consider it necessary" to synthesize them in addition. The inactivated IgE are unable to be fixed on the membranes of corpulent cells and therefore cannot cause the emission of biologically active substances from them.
Thus, the modern programs of extracorporal hemocorrection effectively influences the pathological process, interrupting it at practically all levels. Thus the given methods of treatment, unlike traditional medicamentous therapy, do not load the patient's organism with additional xenobiotics (medicinal and other xenobiotics substances are 'foreign body' food substances which are alien to an organism, and must be metabolized as well as the regular food. Xenobiotics are present in food, delicacies, liquids, liquors, candies, artificial food colors, flavors and preservatives). It is known in fact, that it is common to develop a bronchial asthma long after the administration of any medicines used to promote treatment. Therefore, trying one process of treatment with usual medicamentous therapy at times provokes the development of another problem.
The enumerable programs of extracorporal hemocorrection which we used in the treatment of a significant number of patients demonstrated their high efficiency which considerably exceeded the effectiveness of traditional drug therapy.
The extracorporal hemocorrection procedures provided for a period of 1 - 1.5 weeks, demonstrated in nearly 100% of the cases the suppression of the activity of the process and reduced the patient to the level of proven remission of the preceding 10 - 12 months and more. Thus after these procedures were provided to patients with a hormone dependent variant of bronchial asthma they either did not need supporting hormonal therapy or they required a minimal dose of hormonalpreparations.
Record on consultation:
phone: +7 (499) 324-97-21 - from 900 till 1700
Online-form record on consultation - Round the clock